52 related articles for article (PubMed ID: 15375503)
1. Clinical implications of promoter hypermethylation in RASSF1A and MGMT in retinoblastoma.
Choy KW; Lee TC; Cheung KF; Fan DS; Lo KW; Beaverson KL; Abramson DH; Lam DS; Yu CB; Pang CP
Neoplasia; 2005 Mar; 7(3):200-6. PubMed ID: 15799820
[TBL] [Abstract][Full Text] [Related]
2. Association of promoter methylation of
Din Shah NU; Ali MN; Ganai BA; Mudassar S; Khan MS; Kour J; Waza AA; Rasool MT; Lone AM
Heliyon; 2020 Feb; 6(2):e03488. PubMed ID: 32140600
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of the Ras association domain family 1A (RASSF1A) gene in gallbladder cancer.
Kee SK; Lee JY; Kim MJ; Lee SM; Jung YW; Kim YJ; Park JY; Bae HI; Hong HS; Yun YK; Kim SG; Kim DS
Mol Cells; 2007 Dec; 24(3):364-71. PubMed ID: 18182852
[TBL] [Abstract][Full Text] [Related]
4. Methylation of PCDH17 and NEFH as prognostic biomarker for nonmetastatic RCC: A cohort study.
Koudonas A; Papaioannou M; Kampantais S; Anastasiadis A; Hatzimouratidis K; Dimitriadis G
Medicine (Baltimore); 2022 Jul; 101(28):e29599. PubMed ID: 35838992
[TBL] [Abstract][Full Text] [Related]
5. Tumor Suppressor Function of the SEMA3B Gene in Human Lung and Renal Cancers.
Loginov VI; Dmitriev AA; Senchenko VN; Pronina IV; Khodyrev DS; Kudryavtseva AV; Krasnov GS; Gerashchenko GV; Chashchina LI; Kazubskaya TP; Kondratieva TT; Lerman MI; Angeloni D; Braga EA; Kashuba VI
PLoS One; 2015; 10(5):e0123369. PubMed ID: 25961819
[TBL] [Abstract][Full Text] [Related]
6. Aberrant Promoter Hypermethylation of
Sugara M; Chowdappa R; Kumar KVV; Gawari R; Swamy SN; Kumar SS
Indian J Surg Oncol; 2021 Sep; 12(3):454-459. PubMed ID: 34658570
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation status of
Atmaca HN; Gun S; Onal M; Tural S
Nucleosides Nucleotides Nucleic Acids; 2024 Jun; ():1-13. PubMed ID: 38830238
[TBL] [Abstract][Full Text] [Related]
8. Promoter Hypermethylation of the ATM Gene as a Novel Biomarker for Breast Cancer.
Begam N; Jamil K; Raju SG
Asian Pac J Cancer Prev; 2017 Nov; 18(11):3003-3009. PubMed ID: 29172272
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of the large tumor suppressor genes in Japanese lung cancer.
Sasaki H; Hikosaka Y; Kawano O; Yano M; Fujii Y
Oncol Lett; 2010 Mar; 1(2):303-307. PubMed ID: 22966299
[TBL] [Abstract][Full Text] [Related]
10. Global DNA Hypomethylation and
TuzcuoĞlu P; Özden S
Turk J Pharm Sci; 2020 Jun; 17(3):337-342. PubMed ID: 32636712
[TBL] [Abstract][Full Text] [Related]
11.
Zhuang Q; Chen Z; Shen J; Fan M; Xue D; Lu H; Xu R; He X
Onco Targets Ther; 2019; 12():119-134. PubMed ID: 30588036
[TBL] [Abstract][Full Text] [Related]
12. RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma.
Tezval H; Merseburger AS; Matuschek I; Machtens S; Kuczyk MA; Serth J
BMC Urol; 2008 Sep; 8():12. PubMed ID: 18822131
[TBL] [Abstract][Full Text] [Related]
13. 5-Aza-2'-deoxycytidine suppresses human renal carcinoma cell growth in a xenograft model via up-regulation of the connexin 32 gene.
Hagiwara H; Sato H; Ohde Y; Takano Y; Seki T; Ariga T; Hokaiwado N; Asamoto M; Shirai T; Nagashima Y; Yano T
Br J Pharmacol; 2008 Apr; 153(7):1373-81. PubMed ID: 18264126
[TBL] [Abstract][Full Text] [Related]
14. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
Costa VL; Henrique R; Ribeiro FR; Pinto M; Oliveira J; Lobo F; Teixeira MR; Jerónimo C
BMC Cancer; 2007 Jul; 7():133. PubMed ID: 17645803
[TBL] [Abstract][Full Text] [Related]
15. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis.
Peters I; Rehmet K; Wilke N; Kuczyk MA; Hennenlotter J; Eilers T; Machtens S; Jonas U; Serth J
Mol Cancer; 2007 Jul; 6():49. PubMed ID: 17634119
[TBL] [Abstract][Full Text] [Related]
16. Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.
Tokinaga K; Okuda H; Nomura A; Ashida S; Furihata M; Shuin T
Oncol Rep; 2004 Oct; 12(4):805-10. PubMed ID: 15375503
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
19. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
